Elliot Hirshberg

In this engaging discussion, Elliot Hirshberg, a venture capitalist focused on biotech platforms, and Lada Nuzhna, founder of General Control and biotech analyst, dive into the staggering costs of drug development, revealing it's now $2.5 billion per approval. They explore how China’s fast-tracked trials are reshaping global competitiveness and the significant impact of regulations. The duo muses on how future biotechs might leverage innovative modalities and advanced AI to navigate these challenges and potentially reduce costs.